Healx and SCI Ventures join forces to uncover cures for paralysis with AI-driven drug discovery
Healx, a pioneer in AI-powered drug discovery for rare and neglected conditions, has partnered with SCI Ventures - the world’s first specialist venture fund focused on curing paralysis- to accelerate the discovery and development of therapies for spinal cord injury (SCI) using artificial intelligence. This first-of-its kind collaboration will apply Healx’s cutting-edge AI platform to identify…
Healx and Ovid Therapeutics enter strategic partnership
New York, NY and Cambridge, UK Ovid Therapeutics, a biopharmaceutical company committed to developing medicines that transform the lives of people with neurological diseases, and Healx, the AI-powered, patient-inspired technology company pioneering the next generation of drug discovery, announces that Healx has secured from Ovid an exclusive option to license rights to develop and…
Healx receives IND and Orphan Drug Designation for fragile X clinical trial
Healx has received Investigational New Drug (IND) approval from the US Food and Drug Administration (FDA) for the Phase 2a clinical study of the compound HLX-0201 for Fragile X syndrome. The clinical study will attempt to find at least one novel and effective combination therapy for Fragile X syndrome - the world’s leading inherited cause of autism and learning difficulties which affects roughly…
Healx launches AI-powered indication expansion partnership with Ono Pharmaceutical
Healx, the AI-powered, patient-inspired technology company pioneering the next generation of drug discovery, today announced an exciting partnership with Ono Pharmaceutical Co Ltd, one of Japan’s largest pharmaceutical companies and a global leader in the field of R&D-orientated drug discovery. The collaboration will leverage Healx’s innovative indication expansion technology to identify new…
Healx appoints ex-Dyson and GCHQ as new VP of AI
Healx, the AI-powered, patient-inspired technology company accelerating the discovery and development of rare disease treatments at scale, is thrilled to announce that Andrew Watson has joined its senior leadership team as VP of Artificial Intelligence. In this new role, Andrew will be tasked with scaling Healx’s AI team and strategy to develop best-in-class drug discovery tools and accelerate…
Healx launches partnership with Ataxia UK and FARA to find treatments for rare neurodegenerative condition
Healx, the AI-powered, patient-inspired technology company accelerating the discovery and development of rare disease treatments at scale, is excited to announce its latest patient group partnerships.
Healx and the PKD Charity collaborate to apply AI to the discovery of novel treatments for rare kidney diseases
Healx, the AI-powered, patient-inspired technology company accelerating the discovery and development of rare disease treatments at scale, announced that it would be collaborating with the PKD Charity to identify and progress novel treatments for Autosomal Dominant Polycystic Kidney Disease (ADPKD) and Autosomal Recessive Polycystic Kidney Disease (ARPKD).
Five tips for growing your business and retaining an all-star team in 2021
In Healx's latest blog, Co-Founder and CEO, Tim Guilliams shares his top tips for not just growing but retaining an all-star team this year.
Healx teams up with Mission: Cure to discover and advance the world’s first treatments for chronic pancreatitis
Mission: Cure is a coalition of patients, doctors, researchers and entrepreneurs who are committed to advancing new therapies and cures for currently untreatable diseases. Their primary focus is on chronic pancreatitis, a rare inflammatory condition that affects over a million people across the globe. A new partnership will combine Healx’s AI and drug discovery expertise with Mission: Cure…
How to onboard teams and build strong connections with distributed working
In the first of Healx's new blog series, Senior Director of People, Leigh-Anne Jansen van Rensburg, explores the ways in which Healx has adapted its onboarding processes to offer a fully digital experience to new starters and help them build important connections when working remotely.
Healx’s Rare Treatment Accelerator 2.0 opens to unlock the power of repurposed drugs for rare diseases
Healx, the AI-powered, patient-inspired technology company specialising in treatments for rare diseases, has today opened applications to v.2.0 of its Rare Treatment Accelerator. Building on the success of their v.1.0 call last year, which was focused on patient group partnerships, Healx is now looking to build a global network of academic groups, patient groups and early-stage biotechs to…
Healx teams up with the Foundation for Angelman Syndrome Therapeutics to accelerate novel treatments towards the clinic
Healx, the AI-powered, patient-inspired technology company accelerating the discovery and development of rare disease treatments at scale, is proud to announce its partnership with the Foundation for Angelman Syndrome Therapeutics (FAST) today. This partnership will focus on developing therapies for Angelman syndrome, a rare neurogenetic disorder that affects approximately one in 15,000 people…
Healx and Muscular Dystrophy UK join forces to find new treatments for rare muscle-wasting diseases
Healx, the AI-powered, patient-inspired technology company accelerating the discovery and development of rare disease treatments at scale, today announced its Rare Treatment Accelerator Programme (RTA) partnership with Muscular Dystrophy UK (MDUK).
Meri Williams joins Healx as Chief Technology Officer
Experienced tech leader Meri Williams joins Healx - the AI-powered, patient-inspired technology company - from challenger bank Monzo, as Chief Technology Officer.
Healx partners with Children’s Tumor Foundation to progress neurofibromatosis treatments; recruits patient advocate to lead collaborative drug discovery efforts
Healx, the AI-powered and patient-inspired tech company specialising in accelerating the discovery and development of rare disease treatments, today announced a partnership with US and Europe-based patient group Children’s Tumor Foundation (CTF) to progress new AI-derived therapies for neurofibromatosis (NF).
Healx uses artificial intelligence to find combination drug treatments for COVID-19
Healx, the AI-powered, patient-inspired biotech specialising in rare diseases, today announces it is using its AI platform to develop drug combinations from approved drugs to contribute towards global efforts to find treatments for COVID-19. This focus on combination therapies, where two or more drugs simultaneously target different aspects of the disease pathology, has the potential to ensure a…
Healx appoints Dr Anthony Hall as Chief Medical Officer
Healx, the AI-powered and patient-inspired technology company specialising in finding new treatments for rare diseases, today announced the appointment of Dr Anthony Hall, MB BS BSc, as Chief Medical Officer (CMO).
Healx joins forces with Boehringer Ingelheim to discover new treatment approaches for rare neurological diseases
Healx, the AI-powered biotechnology company focused on developing breakthrough treatments for rare diseases, today announces it has entered into an agreement with Boehringer Ingelheim to identify indications related to rare neurological diseases.
Healx commits $20m to launch Rare Treatment Accelerator programme; appoints Dr Bruce Bloom as Chief Collaboration Officer to lead initiative
Healx, the AI-powered and patient-inspired technology company specialising in treatments for rare diseases, today announces that applications are now being accepted for its Rare Treatment Accelerator (RTA).
Michale Bouskila-Chubb recognised in 50 Movers and Shakers in BioBusiness Report
Healx is delighted to announce that its Head of Business Development, Michale Bouskila-Chubb has been featured in the sixth annual Movers and Shakers in BioBusiness report which showcases the 50 trailblazers shaping the future of the UK life sciences sector.
Healx secures $56m in Series B financing, launches global accelerator programme for rare diseases
Healx, the AI-powered and patient-inspired technology company specialising in treatments for rare diseases, today announces that it has raised $56 million in a Series B financing round, led by one of Europe’s largest VC firms Atomico and joined by Intel Capital, Global Brain and btov Partners.
Healx partners with the ICR to develop potential new AI-derived treatments for rare childhood cancer, DIPG
Healx has announced a collaboration with scientists at The Institute of Cancer Research, London (ICR) to discover new possible ways of treating diffuse intrinsic pontine glioma (DIPG), a life-limiting childhood brain cancer for which no treatments currently exist.
Dr Neil Thompson appointed CSO of Healx to spearhead drug discovery expansion
Healx, the Cambridge (UK) technology company developing breakthrough treatments for rare diseases, is pleased to announce the appointment of Neil Thompson, PhD, as Chief Scientific Officer (CSO).
Kate Hilyard joins Healx to drive the integration of AI with drug discovery for rare diseases
Healx, the Cambridge (UK) technology company developing breakthrough treatments for rare diseases, today announced the appointment of Kate Hilyard PhD as Chief Operating Officer (COO).
Healx raises $10m as investors back AI to find rare disease treatments faster
Healx, the Cambridge (UK) technology company developing breakthrough treatments for rare diseases, has announced a $10 million Series A funding round, led by Balderton Capital, Europe’s leading early-stage venture investor. Existing investors, Jonathan Milner and Amadeus Capital Partners also participated in the round.